Pharmaceutical - USA, Financial

Filter

Current filters:

USAFinancial

Popular Filters

1 to 25 of 82 results

Dendreon seeks a buyer as it files for bankruptcy

Dendreon seeks a buyer as it files for bankruptcy

10-11-2014

US biotech firm Dendreon has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the…

DendreonFinancialOncologyPharmaceuticalProvengeUSA

Salix shares slide on reports of wholesale stock backlog

Salix shares slide on reports of wholesale stock backlog

10-11-2014

Shares in Salix Pharmaceuticals fell nearly 36% after Thursday’s trading as the company cut its 2014…

FinancialPharmaceuticalRelistorRuconestSalix PharmaceuticalsUSA

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

01-11-2014

Just a couple of weeks after abandoning its $54 billion “tax inversion” motivated takeover of Ireland-headquartered…

AbbVieAnti-Arthritics/RheumaticsFinancialHumiraPharmaceuticalShireUSA

Pfizer beats sales and earnings forecast for the third quarter

Pfizer beats sales and earnings forecast for the third quarter

28-10-2014

US pharma giant Pfizer has beaten the forecasts for both its sales and its earnings for the third quarter…

FinancialLyricaPfizerPharmaceuticalUSAViagra

Merck & Co third-qtr disappoints, as earnings plunge

Merck & Co third-qtr disappoints, as earnings plunge

27-10-2014

US pharma giant Merck & Co (NYSE: MRK) posted third-quarter 2014 financial results today, showing that…

FinancialKeytrudaMerck & CoOncologyPharmaceuticalRegulationUSA

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

Eli Lilly hit by patent expirations on Cymbalta and Evista as third-qtr profit drops of 58%

23-10-2014

US drug major Eli Lilly reported third quarter 2014 results that showed how badly the company has been…

CymbaltaEli LillyEli Lilly and CompanyEvistaFinancialPharmaceuticalUnited StatesUSA

Abbott raises midpoint of EPS guidance and sees shares rise as quarterly profit exceeds forecast

Abbott raises midpoint of EPS guidance and sees shares rise as quarterly profit exceeds forecast

22-10-2014

Shares of US health care company Abbott Laboratories rose slightly in the premarket trading period following…

Abbott LaboratoriesFinancialPharmaceuticalUnited StatesUSA

Shire to receive $1.635 billion break fee from AbbVie

Shire to receive $1.635 billion break fee from AbbVie

21-10-2014

The board of Ireland-headquartered drugmaker Shire has said there is now no realistic prospect of AbbVie…

AbbVieBusiness FinanceCity Code on Takeovers and MergersFinancialMergers & AcquisitionsMergers and acquisitionsPharmaceuticalShireUSA

Scientists say USA’s national Alzheimer's plan milestones must be strengthened to meet goal by 2025

20-10-2014

The US government has initiated a major effort to prevent and effectively treat Alzheimer's disease by…

FinancialNeurologicalPharmaceuticalResearchUSA

Orexigen earns total $100 million milestone on Contrave

Orexigen earns total $100 million milestone on Contrave

15-10-2014

US biopharma company Orexigen Therapeutics says it has earned a $70 million milestone payment from partner…

ContraveFinancialMarkets & MarketingMetabolicsOrexigen TherapeuticsPharmaceuticalTakeda PharmaceuticalUSA

New study finds fewer drugs covered by USA’s Medicare

13-10-2014

An analysis of US government data on 2015 Medicare drug plans by HealthPocket has found that the average…

FinancialHealthcarePharmaceuticalUSA

CSL Behring to invest $450 million in capacity expansion

CSL Behring to invest $450 million in capacity expansion

08-10-2014

CSL Behring, a unit of Australia-headquartered CLS Limited, has today announced a multi-year, $450 million…

AlbuminAustraliaBehringCLS LimitedCSL BehringFinancialHealth Medical PharmaHematologyPharmaceuticalUSA

FDA grants to stimulate drug and device development for rare diseases

FDA grants to stimulate drug and device development for rare diseases

01-10-2014

The US Food and Drug Administration yesterday announced it has awarded 15 grants totaling more than $19…

FinancialPharmaceuticalRare diseasesResearchUSA

US pharma and device firms paid doctors/hospitals ~$3.5 billion, CMS data show

US pharma and device firms paid doctors/hospitals ~$3.5 billion, CMS data show

01-10-2014

As part of its ongoing effort to increase transparency and accountability in health care, the Centers…

FinancialMedicare & Medicaid ServicesPharmaceuticalResearchUSA

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

29-09-2014

Achillion Pharmaceuticals is in a prime position to develop its own all-oral hepatitis C treatment as…

Achillion PharmaceuticalsFinancialMarkets & MarketingNephrology and HepatologyPharmaceuticalUSA

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Shire to pay $56.5 million in final agreement with US government

Shire to pay $56.5 million in final agreement with US government

25-09-2014

The US subsidiary of Ireland-headquartered Shire will pay $56.5 million to resolve civil allegations…

AbbVieAdderallFinancialLegalPharmaceuticalShireUSAVyvanse

US Treasury to crack down on tax inversion M&A deals

US Treasury to crack down on tax inversion M&A deals

23-09-2014

The USA’s Department of the Treasury announced on Monday that it is taking action to reduce the tax…

FinancialMergers & AcquisitionsPharmaceuticalPoliticsUSA

Skyepharma will repay 12.7 million euros ahead of Exparel milestone

Skyepharma will repay 12.7 million euros ahead of Exparel milestone

22-09-2014

UK-based Skyepharma, an oral and inhalation drug delivery company, has given notice to CRC European Loan…

AnalgesiaExparelFinancialPacira PharmaceuticalsPharmaceuticalSkyepharmaUKUSA

Report shows Eylea and Lucentis are equally likely to be covered by payers

Report shows Eylea and Lucentis are equally likely to be covered by payers

19-09-2014

Recently launched anti-vascular endothelial growth factor (VEGF) agent Eylea (aflibercept), from USA-based…

EyleaFinancialGenentechLucentisOphthalmicsPharmaceuticalRegeneron PharmaceuticalsUSA

AACR report calls for US cancer funding to be a national priority

AACR report calls for US cancer funding to be a national priority

18-09-2014

Declining budgets have slowed the pace of research into cancer, according to a new report from the American…

AbraxaneCyramzaFinancialGazyvaImbruvicaNexavarOncologyPharmaceuticalResearchTafinlarUSAZydelig

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

15-09-2014

Hostile takeover target Allergan has said that value is what “really matters” in response to Pershing…

AllerganCanadaFinancialLegalPharmaceuticalUSAValeant Pharmaceuticals International

Ablynx launches American Depository Receipt program to expand US investor base

Ablynx launches American Depository Receipt program to expand US investor base

05-09-2014

Belgian drug developer Ablynx has launched a Sponsored Level I American Depository Receipt (ADR) program…

AblynxBusiness FinanceFinancialInvestmentPharmaceuticalStock marketUSA

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

1 to 25 of 82 results

Parexel

Parexel

Back to top